Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-28 00:50:25 - browse：43

A person wears a headset projecting a brain -- health tech coverage from STAT — Adobe

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the neurodegenerative disease.

With the new Series B extension funding, the Cambridge, Mass.-based company has now raised $128 million to develop its headset that uses gamma frequency light and sound stimulation to combat the cognitive decline that’s the hallmark of Alzheimer’s. Cognito is currently undertaking a large study of the treatment and CEO Brent Vaughan told STAT he expects the company to complete the trial and submit data to the Food and Drug Administration for review by the end of 2025.

While under treatment, patients use the device for one hour per day in their homes. The light and sound is supposed to stimulate brain activity that’s disrupted by neurodegenerative conditions, potentially helping to preserve brain structure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout LOUD podcast: A CRISPR milestone, biotech mixology

focus

WSS

Gene editing the human germline: What are the risks?

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout Newsletter: Bluebird, CVS, Contineum

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Wegovy, Zepbound and weight loss drugs that preserve muscle

focus

Wikipedia

hotspot

Psychedelics group wrestles with new pharma identity

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

ChatGPT in medicine: STAT answers readers' burning questions

A daunting task: navigating dual Medicare, Medicaid eligibility

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Anesthesiologist group: stop taking Ozempic before surgery

In key trial, Verve's treatment lowers cholesterol levels in patients

leisure time

Readout LOUD podcast: A CRISPR milestone, biotech mixology

5 to watch: Tech startups trying to solve health care's staffing crisis

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Astellas still sees hope in its gene therapy after four deaths

Baby aspirin cuts fat buildup in liver disease patients, in small study

Morphosys mixed study results for blood cancer drug

focus

focus

Wikipedia

entertainment